Close Menu

Horizon Discovery

Sanyou will use the cell line in the development of preclinical antibody drug projects and to support its customers' human biotherapeutic products.

The deal allows PerkinElmer to expand its portfolio of automated life sciences discovery and applied genomics products to include gene editing and gene modulation tools.

The gene editing and gene modulation technologies firm attributed the decline to the impact of the SARS-CoV-2 pandemic on its research reagents business.

The Cambridge, UK-based firm saw double-digit growth in its screening business and declines in its bioproduction and diagnostics businesses.

The company recently inked deals with Mammoth Biosciences and Rutgers University to license a protein discovery platform and gene editing technology.

The company said revenue growth during the year was driven by performance in its research reagents and screening business units.

The company, which recently signed a licensing agreement with Horizon Discovery, just raised $45 million in a Series B financing round.

Exact Sciences CEO Kevin Conroy discussed the firm's pipeline and plans for 2020 and beyond, while NanoString CEO Brad Gray talked about the company's GeoMx digital spatial profiling technology, among other presentations Wednesday.

Horizon also said it will provide access to the technology to business partners for the development of more effective multi-gene knockout cell therapy programs.

Pages

The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.